News Summary
NegativeGlobe Life missed Q3 earnings expectations and cut FY2026 guidance despite a revenue beat in Q2, driven primarily by CMS processing delays (~$7M impact) and elevated claims severity in its Evry health division. While management attributes issues to specific operational headwinds rather than core business weakness, the company raised buyback authorizations to offset per-share pressure, and Wall Street remains favorably positioned with a Moderate Buy consensus, though shares fell 6.5% post-Q3 results.
Red flags
- •Q3 GAAP EPS miss of 4.7% versus consensus ($4.62 actual vs. ~$4.84 expected)
- •FY2026 EPS guidance cut to $15.35–$15.65 from prior $15.55–$15.95, now below $15.72 consensus
- •CMS Medicare Supplement processing delays causing $7M in excess claims paid in Q3 related to prior periods
- •High-severity claims at Evry (developing group health business) pressuring United American General Agency division results
- •Stock down 6.5% post-Q3 earnings and 7.2% post-Q2 earnings despite revenue beats
Funds Reducing / Exiting (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Maverick Capital | Lee Ainslie | 0 | −11K | — | <0.1% | -100% | EXITED |
| Soros Fund Management | Soros Family Office | 0 | −60K | — | 0.1% | -100% | EXITED |
| Point72 | Steve Cohen | 0 | −42K | — | <0.1% | -100% | EXITED |
Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| MAJORS MICHAEL CLAY | EVP - Chief Strategy Officer | SELL | 14K | $154.48 | $2.22M | 2026-10-23 | ↗ |
| Hensley Robert Edward | EVP & Chief Investment Officer | SELL | 3K | $169.53 | $0.57M | 2026-09-22 | ↗ |
| Hensley Robert Edward | EVP & Chief Investment Officer | SELL | 7K | $170.34 | $1.13M | 2026-09-22 | ↗ |
| MITCHELL ROBERT BRIAN | EVP, General Counsel and CRO | SELL | 1K | $184.75 | $0.19M | 2026-08-07 | ↗ |
| MITCHELL ROBERT BRIAN | EVP, General Counsel and CRO | SELL | 11K | $182.77 | $2.09M | 2026-08-07 | ↗ |
| MITCHELL ROBERT BRIAN | EVP, General Counsel and CRO | SELL | 11K | $183.83 | $1.94M | 2026-08-07 | ↗ |
| Darden James Matthew | Co-Chairman & CEO | SELL | 50K | $182.43 | $9.05M | 2026-07-31 | ↗ |
| Darden James Matthew | Co-Chairman & CEO | SELL | 400 | $183.36 | $0.07M | 2026-07-31 | ↗ |
| Kalmbach Thomas Peter | EVP & CFO | SELL | 3K | $181.23 | $0.48M | 2026-07-30 | ↗ |
| Kalmbach Thomas Peter | EVP & CFO | SELL | 11K | $179.30 | $1.92M | 2026-07-30 | ↗ |
| Kalmbach Thomas Peter | EVP & CFO | SELL | 5K | $180.08 | $0.87M | 2026-07-30 | ↗ |
| Kalmbach Thomas Peter | EVP & CFO | SELL | 3K | $181.81 | $0.51M | 2026-07-30 | ↗ |
| MAJORS MICHAEL CLAY | EVP - Chief Strategy Officer | SELL | 34K | $178.56 | $5.98M | 2026-07-29 | ↗ |
| MAJORS MICHAEL CLAY | EVP - Chief Strategy Officer | SELL | 4K | $179.35 | $0.63M | 2026-07-29 | ↗ |
| Kalmbach Thomas Peter | EVP & CFO | SELL | 12K | $178.73 | $2.20M | 2026-07-28 | ↗ |
| Kalmbach Thomas Peter | EVP & CFO | SELL | 10K | $178.06 | $1.70M | 2026-07-28 | ↗ |
| Kalmbach Thomas Peter | EVP & CFO | SELL | 4K | $179.42 | $0.68M | 2026-07-28 | ↗ |
| Skarjune Dolores L | EVP and Chief Admin. Officer | SELL | 2K | $179.18 | $0.33M | 2026-06-30 | ↗ |
| Hensley Robert Edward | EVP & Chief Investment Officer | SELL | 3K | $145.04 | $0.37M | 2026-03-02 | ↗ |
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| Invesco Ltd. | SC 13G | 4.0M | 5.1% | 2026-05-06 | ↗ |
| Vanguard Capital Management | SC 13G | 5.8M | 7.5% | 2026-04-30 | ↗ |
| Vanguard Portfolio Management | SC 13G | 4.3M | 5.4% | 2026-04-29 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.
Congressional Trading
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Alan Armstrong | senate | — | BUY | $1,001 - $15,000 | 2026-03-27 | 2026-07-21 | ↗ |
Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures.